Calithera Biosciences (CALA) Stock Price, News & Analysis

Company Overview

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 94 shs
• Average Volume: 11,015 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Calithera Biosciences Stock Analysis - MarketRank™

Calithera Biosciences scored higher than 41% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Calithera Biosciences.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.14% of the outstanding shares of Calithera Biosciences have been sold short.

Short Interest Ratio / Days to Cover

Calithera Biosciences has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Calithera Biosciences has recently decreased by 64.95%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Calithera Biosciences does not currently pay a dividend.

Dividend Growth

Calithera Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.11

Percentage of Shares Shorted

0.14% of the outstanding shares of Calithera Biosciences have been sold short.

Short Interest Ratio / Days to Cover

Calithera Biosciences has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Calithera Biosciences has recently decreased by 64.95%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Calithera Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Calithera Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.60% of the stock of Calithera Biosciences is held by insiders.

CALA Stock Analysis - Frequently Asked Questions

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences, Inc. (NASDAQ:CALA) announced its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($3.00) EPS for the quarter, beating analysts' consensus estimates of ($4.60) by $1.60. The biotechnology company had revenue of $6.75 million for the quarter.

When did Calithera Biosciences' stock split?

Shares of Calithera Biosciences reverse split before market open on Wednesday, June 15th 2022.The 1-20 reverse split was announced on Wednesday, June 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Calithera Biosciences?

Shares of CALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Calithera Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX) and First Solar (FSLR).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 8/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CALA
• CIK: 1496671
• Web: www.calithera.com
• Phone: (650) 870-1000
• Fax: N/A
• Employees: 60
• Year Founded: 2010

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 4,870,000
• Free Float: 4,550,000
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -2.82